Neovascular Age-Related Macular Degeneration (Wet AMD) Research & Clinical Trials

Share:

Sponsor - Genentech (Recruiting/Open to Enrollment)

Study: LADDER
A PHASE II, MULTICENTER, RANDOMIZED,  ACTIVE TREATMENT-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF THE RANIBIZUMAB PORT DELIVERY SYSTEM FOR SUSTAINED DELIVERY OF RANIBIZUMAB IN PATIENTS WITH SUBFOVEAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
https://clinicaltrials.gov/ct2/show/NCT02510794?term=LADDER&rank=7

Sponsor – Ohr (Recruiting/Open To Enrollment)

Study: MAKO
A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration
https://clinicaltrials.gov/ct2/show/NCT02727881?term=MAKO&rank=5

Sponsor – Allergan (Closed to Enrollment)

Study: SEQUOIA
SAFETY AND EFFICACY OF ABICIPAR PEGOL (AGN-150998) IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
https://clinicaltrials.gov/ct2/show/NCT02462486?term=ALLERGAN+SEQUOIA&rank=1

Sponsor – Tyrogenex (Closed to Enrollment)

Study: APEX
A RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, DOSE-FINDING, NON-INFERIORITY STUDY OF X-82 PLUS prn EYLEA  COMPARED TO prn EYLEA  MONOTHERAPY IN NEOVASCULAR AMD
https://clinicaltrials.gov/ct2/show/NCT02348359?term=X-82&rank=2

Sponsor – Regeneron (Closed to Enrollment)

Study: ONYX
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF REPEATED DOSES OF INTRAVITREAL REGN910-3 IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
https://clinicaltrials.gov/ct2/show/NCT02713204?term=Regeneron+neovascular+AMD&rank=7

Sponsor – Opthea (Closed to Enrollment)

A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF OPT-302 IN COMBINATION WITH RANIBIZUMAB IN SUBJECTS WITH WET AMD
https://clinicaltrials.gov/ct2/show/NCT02543229?term=Opthea&rank=1

Sponsor – Regeneron (Closed to Enrollment)

Study: CAPELLA
A PHASE 2, DOUBLE-MASKED, RANDOMIZED, CONTROLLED, MULTIPLE-DOSE, REGIMEN-RANGING STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL REGN2176-3 IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
https://clinicaltrials.gov/ct2/show/NCT02418754?term=2176&rank=1

Previous “Wet” AMD Studies:

Principal Investigator 2015 - 2016
Sponsor: Iconic
Study: EMERGE
A PHASE 2 RANDOMIZED, DOUBLE-MASKED, MULTICENTER, ACTIVE-CONTROLLED STUDY EVALUATING ADMINISTRATION OF REPEATED INTRAVITREAL DOSES OF hI-con1 IN PATIENTS WITH CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION
https://clinicaltrials.gov/ct2/show/NCT02358889?term=EMERGE&rank=4

Principal Investigator 2015 - 2016
Sponsor: Neurotech
A MULTI-CENTER, TWO STAGE, OPEN-LABEL PHASE I AND RANDOMIZED ACTIVE CONTROLLED, MASKED PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVITREAL IMPLANTATION OF NT-503-3 ENCAPSULATED CELL TECHNOLOGY COMPARED WITH EYLEA  FOR THE TREAMENT OF RECURRENT SUBFOVEAL CHOROIDAL NEOVASCULARIZATION (CNV) SECONDARY TO AGE-RELATED MACULAR DEGENERATION
https://clinicaltrials.gov/ct2/show/NCT02228304?term=Neurotech&rank=14

Principal Investigator 2014 - 2016
Sponsor: PanOptica
A PHASE I OPEN-LABEL, MUTLI-CENTER TRIAL WITH RANDOMIZATION TO DOSE TO EVALUATE THE SAFETY AND TOLERABILITY OF TOPICAL OCULAR PAN-90806 IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD)
https://clinicaltrials.gov/ct2/results?term=PANOptica&Search=Search

Principal Investigator - 2013-2015
Phase 2 study of the efficacy and safety of Squalamine Lactate Ophthalmic Solution 0.2% twice daily in subjects with neovascular age-related macular degeneration

Principal Investigator, 2013 - 2015
Study: RE-VIEW
An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related
Macular Degeneration

Sub-Investigator, 2010 - 2011
A Randomized, Sham-Injection Controlled, Double-Masked, Multicenter Trial of Ocriplasmin Intravitreal Injection for Treatment of Focal Vitreomacular Adhesion in Subjects with Exudative Age-Related Macular Degeneration (AMD)

Sub-Investigator, 2009 - 2012
Study: HARBOR
A Phase III, Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of 0.5-mg and 2.0-mg Ranibizumab Administered Monthly or on an As-Needed Basis (PRN) with a Safety Run-In of a Single Dose of 2.0-mg Ranibizumab with Subfoveal Neovascular Age-Related Macular Degeneration

Sub-Investigator, 2008 - 2009
A 26-Week, Open Label Study to Assess the Safety and Efficacy of 700µg Dexamethasone Posterior Segment Drug Delivery System Applicator System as Adjunctive Therapy to Lucentis in the Treatment of Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Sub-Investigator, 2008 - 2009
A Phase 2 , Randomized, Masked, Controlled Clinical Study to Assess the Safety and Efficacy of Lucentis  plus Sirolimus versus Lucentis plus Placebo in Patients with Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Sub-Investigator, 2007 - 2009
A Phase 3, Randomized, Double-Masked, Parallel-Assignment Study of Intravitreal Bevasiranib Sodium, Administered every 8 or 12 weeks as Maintenance Therapy Following Three Injections of Lucentis Compared with Lucentis Monotherapy every 4 weeks in Patients with Exudative Age-Related Macular Degeneration (AMD)

Sub-Investigator - 2008
Randomized, controlled trial of VEGF Trap in patients with neovascular AMD

Sub-Investigator, 2008
Study: DENALI
A 24-month Randomized, Double-masked, Controlled, Multicenter, Phase IIIB Study Assessing Safety and Efficacy of Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab Versus Ranibizumab Monotherapy in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Sub-Investigator, 2006 - 2008
A 24-month randomized, double-masked, sham-controlled, multicenter, phase IIIB study comparing photodynamic therapy with verteporfin plus two different dose regimens of intravitreal triamcinolone acetonide (1mg and 4mg) versus Visudyne plus intravitreal pegaptanib (Macugen) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Sub-Investigator, 2006 - 2008 
An Evaluation of Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15mg or 30mg) versus Sham Administration in Patients at Risk for Developing Sight Threatening Choroidal Neovascularization Due to Exudative Age Related Macular Degeneration

Sub-Investigator, 2002 - 2005
An Evaluation of Efficacy and Safety of Posterior Juxtascleral Injections of Anecortave Acetate 15 mg (0.5 mg of 30 mg/ml Anecortave Acetate Sterile Suspension) versus Visudyne in Patients with Subfoveal Exudative Age-Related Macular Degeneration (AMD) Eligible for Initial Treatment with Photodynamic Therapy (PDT) Using Visudyne.

Principal Investigator, 2002 - 2005
A Phase II/III Randomized, Double-Masked, Controlled, Dose Ranging, Multi-Center Comparative Trial, in Parallel Groups, to Establish the Safety and Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients with Exudative Age-Related Macular Degeneration (AMD).

Sub-Investigator, 2000 - 2001
A Phase III, Non-Randomized, Multi-Center, Unmasked Non-placebo Controlled Study of Verteporfin and Macular Degeneration (VAM).

Sub-Investigator, 2005 - 2007
Anecortave Acetate 15 mg Administered Every 3 Months Versus Anecortave Acetate 15 mg Administered Every 6 Months Versus Anecortave Acetate 30 mg Administered Every 6 Months in Patients With Exudative AMD.

Sub-Investigator, 2005
A Phase 3 Multi-Center, Randomized, Double-Masked, Controlled Study of Squalamine Lactate for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration.

Sub-Investigator, 2005
A 24-month Randomized, Double-Masked, Sham-Controlled, Multi-Center, Phase 111B Study Comparing Photodynamic Therapy with Verteporfin Plus Two Different Dose Regimens of Intravitreal Triamcinolone Acetonide (1mg and 4mg) versus Visudyne Plus Intravitreal Pegaptanib (Macugen) in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.

Sub-Investigator, 1998 - 1999
A Phase III Randomized, Multi-Center, Double-Masked, Placebo-Controlled Parallel Group Study of Tin Ethyl Etiopurpurin (SnET2) Photodynamic Therapy in the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration.